



Aptar Pharma Launches First Metal-Free Nasal Spray Pump, Meeting Growing Need for Highly Recyclable Packaging

APF Futurity nasal spray pump certified Highly Recyclable by cyclos-HTP

Crystal Lake, Illinois, January 30, 2023 - Aptar Pharma, part of AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery systems, services and active material science solutions, today announces the launch of APF Futurity, its first metal-free, multidose nasal spray pump developed to deliver nasal saline and other comparable over-the-counter (OTC) formulations.

Specifically designed for recyclability, APF Futurity is Aptar Pharma's first highly recyclable nasal spray pump, having achieved a Class AA certification from cyclos-HTP for recycling streams in Europe¹. APF Futurity is made from polyolefin materials with no metal parts or recycling disruptors, thereby minimizing separation efforts in recycling streams and supporting a higher quality of recyclates.



Gael Touya, President, Aptar Pharma, commented, "As a leading provider of nasal spray pumps globally, the launch of APF Futurity is a significant step forward in our sustainability journey, underlining Aptar's overall commitment to a more circular economy and meeting the global need for sustainable packaging solutions that are easy to recycle."

Part of Aptar Pharma's Futurity sustainable solutions platform, APF Futurity meets a growing consumer need for increased access to recyclable products. In a study conducted by Aptar Pharma in 2022, 77% of respondents indicated that it was 'important' or 'very important' that the products they buy can be recycled².

When used in combination with a high-density polyethylene (HDPE) or polypropylene (PP) container bottle, a product with the APF Futurity pump can be conveniently recycled as one piece when empty after use, with no need to separate or detach any parts or materials before disposal, a key user benefit.

Innovative design based on proven technology

APF Futurity is based on Aptar Pharma's proven Advanced Preservative Free (APF) technology platform, and has been initially developed to deliver multidose nasal saline and comparable OTC formulations. The innovative metal-free pump, for which patent protection has been filed, delivers precise and consistent dosing with soft actuation, with no trade-off on handling and performance.

"APF Futurity is a game-changing innovation for the nasal spray pump industry and I am proud of our design and engineering team for meeting the challenge of designing this metal-free nasal

¹ <https://www.cyclos-htp.de/services/award-use-of-the-label/> - Aptar Pharma's APF futurity nasal spray pump has achieved the cyclos-HTP 'Class AA' recyclable content: > 90% - 95% (highly recyclable) certification in the Netherlands, Germany and Ireland.

² <https://www.aptar.com/resources/meeting-the-worlds-evolving-needs-for-a-more-sustainable-future-how-to-realize-a-circular-approach-to-drug-delivery-solutions>

pump,” stated Stefan Ritsche, President Global Market Development, Consumer Health Care, Aptar Pharma. “This is an important step in the transformation of our nasal spray portfolio to more sustainable solutions, and we look forward to bringing additional innovations of this kind to meet the need in the pharmaceutical industry.”

Aptar’s commitment to sustainability

Driven by our commitment to sustainable practices and products, with a focus on delivering transformative solutions that improve our world, Aptar continues to shape the drug delivery and consumer product dispensing markets.

"Aptar continues to receive recognition for our sustainable product innovations, including the Institute of Packaging Professionals (IOPP) and WorldStar Global Packaging awards, and we were recently ranked #15 on *Newsweek’s* [‘America’s Most Responsible Companies’](#) list,” added Christophe Marie, Product Sustainability Director, Aptar. “Aptar Pharma’s launch of APF Futurity is yet another sustainable product innovation that reinforces our pledge to care for our planet and reduce our environmental impact."

Aptar Pharma will unveil the APF Futurity pump at Pharmapack 2023, which takes place February 1-2, 2023, Paris, France. Visit the [APF Futurity product page](#) for more information.

About Aptar Pharma

Aptar Pharma is part of AptarGroup, Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions and services. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home care, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

This press release contains forward-looking statements. Expressions or future or conditional verbs such as “will” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-Ks and Form 10-Qs. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

###

Aptar Investor Relations Contact:

Mary Skafidas
mary.skafidas@aptar.com
+1 347 351 6407

Aptar Pharma Media Contact:

Carolyn Penot
carolyn.penot@aptar.com
+ 33 6 37 36 76 84

Aptar Media Contact:

Katie Reardon
katie.reardon@aptar.com
+1 815 479 5671